In pediatrics, IL-2 has been used most notably for the treatment of high-risk neuroblastoma in combination with an anti-GD2 monoclonal antibody (mAb) and granulocyte-macrophage colony-stimulating factor (GM-CSF) (21). The gene discussed is IL2; the disease is neuroblastoma.